Canine atopic dermatitis: Role of luteolin as new natural treatment

BACKGROUND: Luteolin has been demonstrated to possess numerous biological effects. However, the effect of luteolin on LPS (Lipopolysaccharides) stimulation in CPEK cells has not been investigated. HYPOTHESIS/OBJECTIVES: An in vitro model of atopic canine dermatitis was used to identify the antioxidant effect of luteolin as a new treatment that is capable of improving the conditions of veterinary patients. METHODS: CPEK cells were treated with or without luteolin in the presence or absence of LPS. A cell viability assay was performed to test luteolin toxicity and the protective effect of luteolin after LPS stimulation. Additionally, enzyme‐linked immunosorbent assay (ELISA) kits were used to detect the levels of IL‐33, IL‐1β, IL‐6, and IL‐8. RESULTS: Luteolin was capable to significantly decrease levels expression of IL‐33, IL 1β, IL‐6, and IL‐8. CONCLUSIONS AND CLINICAL IMPORTANCE: Luteolin could be a new pharmacological treatment for canine atopic dermatitis.